This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

This study is ongoing, but not recruiting participants.
Astellas Pharma Inc
Medivation, Inc.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: July 31, 2007
Last updated: July 28, 2017
Last verified: July 2017
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.

Condition Intervention Phase
Prostate Cancer Hormone Refractory Prostate Cancer Drug: MDV3100 Phase 1

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose-escalation Safety And Pharmacokinetic Study Of Mdv3100 In Patients With Castration-resistant Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety and Tolerability [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Pharmacokinetics, PSA response [ Time Frame: 3 months ]

Enrollment: 140
Actual Study Start Date: July 23, 2007
Estimated Study Completion Date: December 31, 2017
Primary Completion Date: December 8, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: MDV3100
MDV3100 daily until progression or dose-limiting toxicity
Other Names:
  • enzalutamide
  • Xtandi

Detailed Description:
This is a Phase 1, open-label, uncontrolled, dose-escalation study with dose-expansion at doses determined to be tolerated. Patients who tolerate the drug and do not progress will be allowed to continue treatment. The study endpoints are safety and tolerability and pharmacokinetics. PSA values will also be collected to look for PSA response.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologically confirmed adenocarcinoma of the prostate;
  2. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or inhibitor, or orchiectomy (i.e., surgical or medical castration);
  3. Progressive disease after medical or surgical castration,

Exclusion Criteria:

1. Metastases in the brain or active epidural disease. (Note: patients with treated epidural disease are allowed);

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00510718

United States, Massachusetts
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, United States, 02215
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
MSKCC- Sidney Kimmel Center
New York, New York, United States, 10065
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
United States, Texas
Investigational Pharmacy Services
Houston, Texas, United States, 77030-4009
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030-4009
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
University of Washington Medical Center
Seattle, Washington, United States, 98195
Sponsors and Collaborators
Astellas Pharma Inc
Medivation, Inc.
Study Director: Pfizer Pfizer Call Center Pfizer
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pfizer Identifier: NCT00510718     History of Changes
Obsolete Identifiers: NCT00513812
Other Study ID Numbers: S-3100-1-01
C3431009 ( Other Identifier: Alias Study Number )
Study First Received: July 31, 2007
Last Updated: July 28, 2017

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases processed this record on August 18, 2017